{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 42,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a bar chart to demonstrate efficacy in an animal model and an icon grid to summarize clinical benefits.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/41",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.19
      },
      "kind": "callout",
      "text": "Enhanced pro-social effects with potentially reduced side effects compared to MDMA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d4486a3-87d4-409b-a248-59d886f9299d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "chart",
      "text": "Increased duration of interaction in the three-chamber social interaction test",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6db657e8-ebd5-43e3-938b-6683ea14edc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "image",
      "text": "less stimulant activity, increased social interaction, increasing feelings of connectedness, reduced dopamine-related adverse effects",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0987574b-95b1-47b2-9a61-1a39e0cb803b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.037,
        "y": 0.16
      },
      "kind": "list",
      "text": "MM402 is the serotonergic enantiomer of MDMA\nPotential first-in-class therapy for core symptoms of ASD\nIntend to develop for daily, at-home use",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0190f93e-bd1b-4a7f-85ec-cbbfa916281d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.17,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. “MM402 demonstrates better efficacy than S(+)-3,4-MDMA or (±)-3,4-MDMA in Fmr1 knockout mice, an animal model of autism spectrum disorder”. Presented at ECNP 2023. Data from “stranger” portion of “Duration in the arena” data.\n2. Pitts EG, Curry DW, Hampshire KN et al. 2018; Psychopharmacology; 235(2):377-392.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5e05a28-426e-402b-a95e-6e3f75a6e741",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.53,
        "x": 0.037,
        "y": 0.045
      },
      "kind": "title",
      "text": "Addressing the Urgent Need For Novel ASD Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e80d3045-8d85-4922-bc0c-91deffd6b299",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "97416368-d7a5-4de5-bda7-a00b9d86239d",
      "evidence": "list/bullet: MM402 is the serotonergic enantiomer of MDMA Potential first-in-class therapy for core symptoms of ASD Intend to develop for daily, at-home use",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "iconography",
      "slug": null,
      "matchId": "b1899183-bfaa-4171-ab20-2baf2a4507e0",
      "evidence": "Use of icons to categorize therapeutic benefits",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}